Main Menu


Publications Highlights View all by category

Types of Publications

Journal Articles

Smrke, A.M. Huang, P.H. Jones, R.L. (2021). Sirolimus for patients with progressive epithelioid hemangioendothelioma. Cancer, Vol.127 (4), pp. 504-506.

Smrke, A. Anderson, P.M. Gulia, A. Gennatas, S. Huang, P.H. Jones, R.L. (2021). Future Directions in the Treatment of Osteosarcoma. Cells, Vol.10 (1).  show abstract

Peck, B. Bland, P. Mavrommati, I. Muirhead, G. Cottom, H. Wai, P.T. Maguire, S.L. Barker, H.E. Morrison, E. Kriplani, D. Yu, L. Gibson, A. Falgari, G. Brennan, K. Farnie, G. Buus, R. Marlow, R. Novo, D. Knight, E. Guppy, N. Kolarevic, D. Susnjar, S. Milijic, N.M. Naidoo, K. Gazinska, P. Roxanis, I. Pancholi, S. Martin, L.-. Holgersen, E.M. Cheang, M.C. Noor, F. Postel-Vinay, S. Quinn, G. McDade, S. Krasny, L. Huang, P. Daley, F. Wallberg, F. Choudhary, J.S. Haider, S. Tutt, A.N. Natrajan, R. (2021). 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer research, Vol.81 (4), pp. 847-859.

Lima, N.C. Atkinson, E. Bunney, T.D. Katan, M. Huang, P.H. (2020). Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. Int j mol sci, Vol.21 (9).  show abstract

Cojocaru, E. Wilding, C. Engelman, B. Huang, P. Jones, R.L. (2020). Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. Current molecular biology reports, Vol.6 (1), pp. 1-9.  show abstract

Harrison, P.T. Vyse, S. Huang, P.H. (2020). Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Seminars in cancer biology, Vol.61, pp. 167-179.

Burns, J. Wilding, C.P. L Jones, R. H Huang, P. (2020). Proteomic research in sarcomas – current status and future opportunities. Seminars in cancer biology, Vol.61, pp. 56-70.

Wilding, C.P. Loong, H.H. Huang, P.H. Jones, R.L. (2020). Tropomyosin receptor kinase inhibitors in the management of sarcomas. Current opinion in oncology, Vol.32 (4), pp. 307-313.

Smrke, A. Gennatas, S. Huang, P. Jones, R.L. (2020). Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future oncol, Vol.16 (22), pp. 1639-1646.  show abstract

Krasny, L. Huang, P.H. (2020). Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Mol omics, .  show abstract

Chen, T.W. Burns, J. Jones, R.L. Huang, P.H. (2020). Optimal Clinical Management and the Molecular Biology of Angiosarcomas. Cancers (basel), Vol.12 (11).  show abstract

COJOCARU, E. THWAY, K. FISHER, C. MESSIOU, C. ZAIDI, S. MIAH, A.B. BENSON, C. GENNATAS, S. HUANG, P. JONES, R.L. (2020). Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer research, Vol.40 (12), pp. 7003-7007.

Krasny, L. Bland, P. Burns, J. Lima, N.C. Harrison, P.T. Pacini, L. Elms, M.L. Ning, J. Martinez, V.G. Yu, Y.-. Acton, S.E. Ho, P.-. Calvo, F. Swain, A. Howard, B.A. Natrajan, R.C. Huang, P.H. (2020). A mouse SWATH-mass spectrometry reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts. Dis model mech, Vol.13 (7).  show abstract

Wilding, C.P. Elms, M.L. Judson, I. Tan, A.-. Jones, R.L. Huang, P.H. (2019). The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert review of anticancer therapy, Vol.19 (11), pp. 971-991.

Chamberlain, F.E. Wilding, C. Jones, R.L. Huang, P. (2019). Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert opinion on investigational drugs, Vol.28 (6), pp. 505-511.

Martinez, V.G. Pankova, V. Krasny, L. Singh, T. Makris, S. White, I.J. Benjamin, A.C. Dertschnig, S. Horsnell, H.L. Kriston-Vizi, J. Burden, J.J. Huang, P.H. Tape, C.J. Acton, S.E. (2019). Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. Cell reports, Vol.29 (9), pp. 2810-2822.e5.

Vyse, S. Huang, P.H. (2019). Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal transduction and targeted therapy, Vol.4 (1).

Lee, A.T. Chew, W. Wilding, C.P. Guljar, N. Smith, M.J. Strauss, D.C. Fisher, C. Hayes, A.J. Judson, I. Thway, K. Jones, R.L. Huang, P.H. (2019). The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Scientific reports, Vol.9 (1).  show abstract

Lee, A.T. Jones, R.L. Huang, P.H. (2019). Pazopanib in advanced soft tissue sarcomas. Signal transduction and targeted therapy, Vol.4 (1).

Vyse, S. McCarthy, F. Broncel, M. Paul, A. Wong, J.P. Bhamra, A. Huang, P.H. (2018). Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. Journal of proteomics, Vol.170, pp. 130-140.

Antoniou, G. Lee, A.T. Huang, P.H. Jones, R.L. (2018). Olaratumab in soft tissue sarcoma – Current status and future perspectives. European journal of cancer, Vol.92, pp. 33-39.

Jenks, A.D. Vyse, S. Wong, J.P. Kostaras, E. Keller, D. Burgoyne, T. Shoemark, A. Tsalikis, A. de la Roche, M. Michaelis, M. Cinatl, J. Huang, P.H. Tanos, B.E. (2018). Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer. Cell reports, Vol.23 (10), pp. 3042-3055.

Luczynski, M.T. Harrison, P.T. Lima, N. Krasny, L. Paul, A. Huang, P.H. (2018). Spatial localisation of Discoidin Domain Receptor 2 (DDR2) signalling is dependent on its collagen binding and kinase activity. Biochemical and biophysical research communications, Vol.501 (1), pp. 124-130.

Lee, A.T. Thway, K. Huang, P.H. Jones, R.L. (2018). Clinical and Molecular Spectrum of Liposarcoma. Journal of clinical oncology, Vol.36 (2), pp. 151-159.  show abstract

Harrison, P.T. Huang, P.H. (2018). Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. Essays biochem, Vol.62 (4), pp. 583-593.  show abstract

Krasny, L. Bland, P. Kogata, N. Wai, P. Howard, B.A. Natrajan, R.C. Huang, P.H. (2018). SWATH mass spectrometry as a tool for quantitative profiling of the matrisome. J proteomics, Vol.189, pp. 11-22.  show abstract

Tan, A.-. Vyse, S. Huang, P.H. (2017). Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug discovery today, Vol.22 (1), pp. 72-84.

Huang, P.H. (2017). Targeting SWI/SNF mutant cancers with tyrosine kinase inhibitor therapy. Expert review of anticancer therapy, Vol.17 (1), pp. 1-3.

Lee, A.T. Pollack, S.M. Huang, P. Jones, R.L. (2017). Phase III Soft Tissue Sarcoma Trials: Success or Failure?. Current treatment options in oncology, Vol.18 (3).

Polychronidou, G. Karavasilis, V. Pollack, S.M. Huang, P.H. Lee, A. Jones, R.L. (2017). Novel therapeutic approaches in chondrosarcoma. Future oncology, Vol.13 (7), pp. 637-648.

Vyse, S. Howitt, A. Huang, P.H. (2017). Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. Journal of molecular biology, Vol.429 (12), pp. 1767-1786.

Lima, N. Lee, A. Huang, P.H. (2017). Progress and impact of clinical phosphoproteomics on precision oncology. Translational cancer research, .  show abstract

Vyse, S. Desmond, H. Huang, P.H. (2017). Advances in mass spectrometry based strategies to study receptor tyrosine kinases. Iucrj, Vol.4, pp. 119-130.  show abstract

Payne, L.S. Huang, P.H. (2017). Targeted Analysis of Phosphotyrosine Signaling by Multiple Reaction Monitoring Mass Spectrometry. , , pp. 263-281.

Broncel, M. Huang, P.H. (2017). Analysis of Phosphotyrosine Signaling Networks in Lung Cancer Cell Lines. , , pp. 253-262.

Lee, A. Huang, P. DeMatteo, R.P. Pollack, S.M. (2016). Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away. American society of clinical oncology educational book. american society of clinical oncology. annual meeting, Vol.35, pp. 281-290.  show abstract

Krasny, L. Paul, A. Wai, P. Howard, B.A. Natrajan, R.C. Huang, P.H. (2016). Comparative proteomic assessment of matrisome enrichment methodologies. Biochemical journal, Vol.473 (21), pp. 3979-3995.  show abstract

Noujaim, J. Payne, L.S. Judson, I. Jones, R.L. Huang, P.H. (2016). Phosphoproteomics in translational research: a sarcoma perspective. Annals of oncology, Vol.27 (5), pp. 787-794.

Wong, J.P. Todd, J.R. Finetti, M.A. McCarthy, F. Broncel, M. Vyse, S. Luczynski, M.T. Crosier, S. Ryall, K.A. Holmes, K. Payne, L.S. Daley, F. Wai, P. Jenks, A. Tanos, B. Tan, A.-. Natrajan, R.C. Williamson, D. Huang, P.H. (2016). Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. Cell reports, Vol.17 (5), pp. 1265-1275.

Maguire, S.L. Peck, B. Wai, P.T. Campbell, J. Barker, H. Gulati, A. Daley, F. Vyse, S. Huang, P. Lord, C.J. Farnie, G. Brennan, K. Natrajan, R. (2016). Three‐dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. The journal of pathology, Vol.240 (3), pp. 315-328.

Lee, A. Huang, P.H. Pollack, S.M. Jones, R.L. (2016). Drug Repositioning in Sarcomas and Other Rare Tumors. Ebiomedicine, .

Corallino, S. Iwai, L.K. Payne, L.S. Huang, P.H. Sacco, F. Cesareni, G. Castagnoli, L. (2016). Alterations in the phosphoproteomic profile of cells expressing a non-functional form of the SHP2 phosphatase. N biotechnol, Vol.33 (5 Pt A), pp. 524-536.  show abstract

Todd, J.R. Ryall, K.A. Vyse, S. Wong, J.P. Natrajan, R.C. Yuan, Y. Tan, A.-. Huang, P.H. (2016). Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. Oncotarget, Vol.7 (39), pp. 62939-62953.  show abstract

Tan, A.C. Ryall, K.A. Huang, P.H. (2016). Expanding the computational toolbox for interrogating cancer kinomes. Pharmacogenomics, Vol.17 (2), pp. 95-97.

Huang, P.H. Cook, R. Zoumpoulidou, G. Luczynski, M.T. Mittnacht, S. (2015). Retinoblastoma family proteins: new players in DNA repair by non-homologous end-joining. Molecular and cellular oncology, .  show abstract

Huang, P.H. Cook, R. Mittnacht, S. (2015). RB in DNA repair. Oncotarget, Vol.6 (25), pp. 20746-20747.

Cook, R. Zoumpoulidou, G. Luczynski, M.T. Rieger, S. Moquet, J. Spanswick, V.J. Hartley, J.A. Rothkamm, K. Huang, P.H. Mittnacht, S. (2015). Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining. Cell rep, Vol.10 (12), pp. 2006-2018.  show abstract

Payne, L.S. Huang, P.H. (2014). Discoidin domain receptor 2 signaling networks and therapy in lung cancer. J thorac oncol, Vol.9 (6), pp. 900-904.  show abstract

Iwai, L.K. Luczynski, M.T. Huang, P.H. (2014). Discoidin domain receptors: a proteomic portrait. Cell mol life sci, Vol.71 (17), pp. 3269-3279.  show abstract

Fu, H.-. Valiathan, R.R. Payne, L. Kumarasiri, M. Mahasenan, K.V. Mobashery, S. Huang, P. Fridman, R. (2014). Glycosylation at Asn211 regulates the activation state of the discoidin domain receptor 1 (DDR1). J biol chem, Vol.289 (13), pp. 9275-9287.  show abstract

Iwai, L.K. Chang, F. Huang, P.H. (2013). Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation. Cell adh migr, Vol.7 (2), pp. 161-164.  show abstract

Payne, L.S. Huang, P.H. (2013). The pathobiology of collagens in glioma. Mol cancer res, Vol.11 (10), pp. 1129-1140.  show abstract

Iwai, L.K. Payne, L.S. Luczynski, M.T. Chang, F. Xu, H. Clinton, R.W. Paul, A. Esposito, E.A. Gridley, S. Leitinger, B. Naegle, K.M. Huang, P.H. (2013). Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochem j, Vol.454 (3), pp. 501-513.  show abstract

Fu, H.-. Valiathan, R.R. Arkwright, R. Sohail, A. Mihai, C. Kumarasiri, M. Mahasenan, K.V. Mobashery, S. Huang, P. Agarwal, G. Fridman, R. (2013). Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J biol chem, Vol.288 (11), pp. 7430-7437.  show abstract

Huang, P.H. (2012). Phosphoproteomic studies of receptor tyrosine kinases: future perspectives. Mol biosyst, Vol.8 (4), pp. 1100-1107.  show abstract

Hedgethorne, K. Huang, P.H. (2012). Dacomitinib Pan-ErbB inhibitor, Oncolytic. Drugs of the future, Vol.37 (6), pp. 393-401.

Xu, H. Bihan, D. Chang, F. Huang, P.H. Farndale, R.W. Leitinger, B. (2012). Discoidin domain receptors promote α1β1- and α2β1-integrin mediated cell adhesion to collagen by enhancing integrin activation. Plos one, Vol.7 (12), p. e52209.  show abstract

Suwaki, N. Vanhecke, E. Atkins, K.M. Graf, M. Swabey, K. Huang, P. Schraml, P. Moch, H. Cassidy, A.M. Brewer, D. Al-Lazikani, B. Workman, P. De-Bono, J. Kaye, S.B. Larkin, J. Gore, M.E. Sawyers, C.L. Nelson, P. Beer, T.M. Geng, H. Gao, L. Qian, D.Z. Alumkal, J.J. Thomas, G. Thomas, G.V. (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci transl med, Vol.3 (85), p. 85ra47.  show abstract

Hedgethorne, K. Huang, P.H. (2010). FORETINIB. Drugs of the future, Vol.35 (11), pp. 893-9.

Huang, P.H. Miraldi, E.R. Xu, A.M. Kundukulam, V.A. Del Rosario, A.M. Flynn, R.A. Cavenee, W.K. Furnari, F.B. White, F.M. (2010). Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol biosyst, Vol.6 (7), pp. 1227-1237.  show abstract

Xu, A.M. Huang, P.H. (2010). Receptor tyrosine kinase coactivation networks in cancer. Cancer res, Vol.70 (10), pp. 3857-3860.  show abstract

Pines, G. Huang, P.H. Zwang, Y. White, F.M. Yarden, Y. (2010). EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene, Vol.29 (43), pp. 5850-5860.  show abstract

Joughin, B.A. Naegle, K.M. Huang, P.H. Yaffe, M.B. Lauffenburger, D.A. White, F.M. (2009). An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Mol biosyst, Vol.5 (1), pp. 59-67.  show abstract

Huang, P.H. Xu, A.M. White, F.M. (2009). Oncogenic EGFR signaling networks in glioma. Sci signal, Vol.2 (87), p. re6.  show abstract

Huang, P.H. Marais, R. (2009). Cancer: Melanoma troops massed. Nature, Vol.459 (7245), pp. 336-337.

Huang, P.H. White, F.M. (2008). Phosphoproteomics: unraveling the signaling web. Mol cell, Vol.31 (6), pp. 777-781.  show abstract

Wilker, E.W. van Vugt, M.A. Artim, S.A. Huang, P.H. Petersen, C.P. Reinhardt, H.C. Feng, Y. Sharp, P.A. Sonenberg, N. White, F.M. Yaffe, M.B. (2007). 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature, Vol.446 (7133), pp. 329-332.  show abstract

Huang, P.H. Cavenee, W.K. Furnari, F.B. White, F.M. (2007). Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell cycle, Vol.6 (22), pp. 2750-2754.  show abstract

Huang, P.H. Mukasa, A. Bonavia, R. Flynn, R.A. Brewer, Z.E. Cavenee, W.K. Furnari, F.B. White, F.M. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc natl acad sci u s a, Vol.104 (31), pp. 12867-12872.  show abstract


Tan, A.-. Huang, P.H. (2017). Kinase Signaling Networks, Humana Press, ISBN: 9781493971527.

Fridman, R. Huang, P.H. (2016). Discoidin Domain Receptors in Health and Disease, 1.Springer-Verlag New York, ISBN: 978-1-4939-6383-6.

Book Chapters

Iwai, L.K. Payne, L.S. Allam, D. Huang, P.H. (2016). Discoidin Domain Receptor Signaling Networks. In Fridman, R.Huang, P.H. (Eds.), Discoidin Domain Receptors in Health and Disease. Springer-Verlag New York, ISBN: 978-1-4939-6383-6.

Huang, P.H. White, F.M. (2009). Selecting optimum combinations for therapeutic treatment of brain tumors using quantitative analysis of signaling networks. In Meir, E.G. (Ed.), CNS Cancer, Models, Prognostic Factors and Targets. (pp. 953-1284). Humana Press, ISBN: 9781603275521.

White, F.M. Huang, P.H. Farley, A. (2009). Phosphopeptide analysis using IMAC and mass spectrometry. In Link, A.J.LaBaer, J. (Eds.), Proteomics. (p. 228). Cold Spring Harbor Laboratory Pr, ISBN: 9780879697877.

Patents and patent applications

Wong, J.Huang, P.H. Methods and materials for treating cancer.